AAPS PharmSci 360 2024: Drug Delivery in Early Development

As a preview of what’s to come at this year’s AAPS PharmSci 360, being held Oct. 20–23, 2024 in Salt Lake City, UT, Pharmaceutical Technology® sat down with Erica Schlesinger, vice president of Technical Development at Serán Bioscience, to talk about her prologue for AAPS PharmSci 360 2024 and what drives the choice of delivery method for new modalities.

“[A]s biologics have emerged as one of the more common therapeutic areas, we've really been looking at how we can improve the patient experience and make these more widely applicable and safer to administer. And a lot of that focus is on how to convert from IV [intravenous] formulations to subcutaneous formulations and subcutaneous administration. And you know, in order to do that, we need to be able to deliver more drug in smaller volumes or more drug in systems that don't need to be administered through IV,” says Schlesinger in the interview. “I think the other area that's been a huge focus area in the past couple years has really been looking at how we can deliver biomolecules and other low-permeability pharmaceuticals systemically through the oral delivery route by leveraging permeation enhancers.”

Click the above video to watch the full interview.

Schlesinger’s prologue presentation can be accessed from the AAPS PharmSci 360 website. She will also be moderating the presentation, Assessment of Permeability: Bridging Traditional and Novel Compounds in Discovery, at AAPS PharmSci 360, on Monday, Oct. 21, 2024 in Salt Lake City, UT.